Back to search

Nucleome Therapeutics Limited

12109297

active
Private Limited Company
Companies House
Health Score
75 / 100

Some Concerns

25/30
Filing
10/30
Financial
40/40
Risk
  • No accounts filed in last 18 months (-5)
  • Current liabilities exceed current assets (-10)

Details

NUCLEOME THERAPEUTICS LIMITED, INVENTA, OXFORD, OX2 0HA
Incorporated 17/07/2019

Compliance

Accounts

Up to date

Confirmation statement

Up to date

Industry

72110
Research and experimental development on biotechnology

Officers

James Raymond Hughes

director · Since 17/07/2019

ASSOCIATE PROFESSOR AT UNIVERSITY OF OXF

BRITISH,IRISH · UNITED KINGDOM · Age 57

Dr Jonathan Paul Hepple

director · Since 30/11/2020

VENTURE CAPITALIST

BRITISH · UNITED KINGDOM · Age 55

Also on 1 other board

Dr Rana Abdul Raouf Al-Hallaq

director · Since 21/10/2022

PARTNER, PFIZER VENTURES EXECUTIVE DIREC

AMERICAN · UNITED STATES · Age 51

Also on 1 other board

Dr Bauke Anninga

director · Since 21/10/2022

VENTURE CAPITALIST

DUTCH · NETHERLANDS · Age 39

Also on 1 other board

Dr Russell George Greig

director · Since 06/09/2023

CHAIR

AMERICAN,BRITISH · UNITED STATES · Age 74

John Davis

director · Since 15/02/2024

PHYSICIAN

AMERICAN · UNITED STATES · Age 64

Mark Bodmer

director · Since 24/07/2024

CEO

BRITISH · UNITED KINGDOM · Age 69

Dr Nadiya Ishnazarova

director · Since 04/12/2025

RUSSIAN · NETHERLANDS · Age 34

Persons with Significant Control

Oxford Science Enterprises Plc

25–50% votes

46, Woodstock Road, Oxford, OX2 6HT

Reg: 09093331 · Companies House · Corporate

Notified 02/08/2019

Former PSCs

James Raymond Hughes

Ceased 29/07/2019

CompanyRankvs 1850+ SIC 72110 peers
78

Financial strength97th percentile among SIC peers · 24/25
Employees81th percentile among SIC peers · 12/15
LiquidityCurrent ratio 89.06× · 20/20
Longevity7 years trading (max 15) · 7/15
Filing complianceAll filings up to date · 15/15
Show leaderboard
1Werfen Limited
90
2Biopharma Process Systems Limited
90
3Theradex (Europe) Limited
90
4Spicer Consulting Limited
90
5Exmoor Pharma Concepts Limited
90
6Ubc Late Stage (Uk) Limited
90
7Wuxi Apptec Uk Ltd
90
8Labgenius Limited
89
9Nuclera Ltd
88
10Aparito Limited
87
185Nucleome Therapeutics Limited
78
How is this score calculated?
Financial strength24/25 pts

Net worth compared to all companies in the same SIC code with published accounts. Top quartile earns the full 25 points.

Employees12/15 pts

Workforce size relative to sector peers from the most recent accounts. A larger team generally signals commercial scale.

Liquidity20/20 pts

Current assets ÷ current liabilities. A ratio above 2× earns full marks; between 1–2× scores partially; below 0.5× scores minimal points.

Longevity7/15 pts

One point per year of operation since incorporation, capped at 15. Older companies have a proven track record.

Filing compliance15/15 pts

Full 15 points when both annual accounts and confirmation statement are filed on time. Points are deducted for each overdue filing.

Maximum score is 100. Deductions apply for insolvency history, outstanding charges, going concern doubt, or disqualified officers.

Key FinancialsYear ending 31/07/2020

Net Worth

£4.7M

Balance sheet strength

Cash

£4.4M

Cash in the bank

Net Current Assets

£4.5M

Working capital

Current Assets

£4.5M

Current Liabilities

£51k

Fixed Assets

£204k

Debtors

£126k

4avg. employees

Balance Sheet

Intangible assets£77k
Assets less current liabilities£4.7M
Prepared with Caseware UK (AP4) 2019.0.227

EstimatesDerived

YearCurrent Ratio
202089.06

Derived from filed accounts. Not audited figures.